Robert Beall, a 63-year-old biochemist turned patient advocate, believes it is past time for charities to change their approach to finding treatments and cures. "By absorbing some of the early financial risk involved in developing new drugs, philanthropists can increase the odds that a company will take on a small disease such as cystic fibro-sis," says Beall, who heads the Cystic Fibrosis Foundation (CFF), a medical charity based in Bethesda, Maryland, with assets totalling US$230 million.
展开▼
